NCT05758493View on ClinicalTrials.gov

Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

December 10, 2027

Study Completion Date

March 10, 2028

Conditions
AmyloidosisTransthyretin Amyloidosis
Interventions
DIAGNOSTIC_TEST

124I-Evuzamitide

Amyloid reactive protein used as imaging agent to detect systemic amyloidosis

Trial Locations (1)

97239

RECRUITING

Oregon Health & Science University, Portland

Sponsors

Collaborators (1)

Attralus, Inc.
All Listed Sponsors
collaborator

Attralus, Inc.

INDUSTRY

lead

Oregon Health and Science University

OTHER